Nateglinide restores early-phase insulin secretion in type 2 diabetes

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1272, 2001-01, pp. : 9-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The oral antihyperglycaemic agent nateglinide [`Starlix'] has been approved in Switzerland for the treatment of type 2 diabetes mellitus.

Inpharma, Vol. 1, Iss. 1259, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Multicentre, Double-blind, Randomized Study of Mitiglinide Compared with Nateglinide in Type 2 Diabetes Mellitus Patients in China

By Gao X

The Journal of International Medical Research, Vol. 37, Iss. 3, 2009-05 ,pp. : 812-821

Field House Publishing

Access to resources Recommend Favorite

In Finland, repaglinide is dominant to nateglinide as combination therapy with metformin for the treatment of type 2 diabetes mellitus inadequately controlled with monotherapy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 507, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Insulin sensitisation in the treatment of Type 2 diabetes

By Tadayyon M Smith SA

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 307-324

Informa Healthcare

Access to resources Recommend Favorite

Insulin detemir weighs in against insulin glargine in type 2 diabetes

Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite